Dr. Lipson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
201 North Broadway Street
Viragh BLDG 5th FL
Baltimore, MD 21287Phone+1 410-955-8964Fax+1 410-367-2194
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2008 - 2011- Johns Hopkins UniversityResidency, Internal Medicine, 2005 - 2008
Icahn School of Medicine at Mount SinaiClass of 2005
Certifications & Licensure
FL State Medical License 2022 - Present
DC State Medical License 2012 - 2026
MD State Medical License 2008 - 2026
PA State Medical License 2024 - 2026
VA State Medical License 2021 - 2026
DE State Medical License 2022 - 2023
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Clinical Trials
- Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma Start of enrollment: 2018 Nov 27
- Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers Start of enrollment: 2019 Nov 08
- Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer Start of enrollment: 2024 Aug 11
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study.Yujie Zhao, Jacqueline T Ferri, James R White, Megan D Schollenberger, Kim Peloza
Microbiology Spectrum. 2025-02-03 - Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockade.Stephanie L Alden, Soren Charmsaz, Howard L Li, Hua-Ling Tsai, Ludmila Danilova
Journal for Immunotherapy of Cancer. 2025-01-19 - 3 citationsImmune-related encephalitis after immune checkpoint inhibitor therapy.Monica W Buckley, Aanika Balaji Warner, Julie Brahmer, Laura C Cappelli, William H Sharfman
The Oncologist. 2025-01-17
Journal Articles
- From Validity to Clinical Utility: The Influence of Circulating Tumor DNA on Melanoma Patient Management in a Real‐World SettingKaren B Bleich, William H Sharfman, Steven P Rowe, Evan J Lipson, Megan D Schollenberger, Molecular Oncology
- Nodular Regenerative Hyperplasia Associated with Immune Checkpoint BlockadeEvan J Lipson, Michael I Brener, Jaclyn LoPiccolo, James P Hamilton, Hepatology
Press Mentions
Toxic Trade-OffsMarch 16th, 2023- Evan Lipson, MD, on Nivolumab plus Relatlimab for Advanced MelanomaJuly 14th, 2022
- ASCO: Nivolumab, Relatlimab Combo Slows Advanced MelanomaMay 30th, 2021
- Join now to see all
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/evan-lipson
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
